PFIZER INC PFE Income Statement

Pfizer inc (PFE)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jul'18	Apr'18	Dec'17	Sep'17	Jul'17	Apr'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09	Sep'08	Jun'08
Revenues
50,660	51,750	53,039	53,657	53,859	53,647	53,373	53,243	52,673	52,546	52,470	0	0	52,824	53,244	52,286	50,992	48,851	47,922	48,196	49,116	49,605	50,045	50,327	50,527	51,584	50,877	51,187	52,182	54,657	53,245	56,901	59,418	61,035	65,058	64,444	65,091	65,165	65,500	61,126	54,978	49,269	45,445	45,953	0	0	0
Costs and expenses:
Cost of sales
10,164	10,219	10,686	10,778	11,118	11,248	11,429	11,579	11,323	11,228	11,184	0	0	12,322	12,521	11,655	10,661	9,648	8,939	9,088	9,370	9,577	9,669	9,588	9,368	9,586	9,183	9,205	9,339	9,821	9,257	10,357	11,552	12,500	13,785	14,166	14,279	14,788	15,182	13,181	11,253	8,459	7,075	7,575	0	0	0
Selling, informational and administrative expenses
13,884	14,350	14,117	14,351	14,382	14,455	15,003	15,013	14,901	14,804	14,678	0	0	14,844	15,464	15,175	15,090	14,809	13,741	14,027	14,161	14,097	14,268	14,107	14,178	14,355	14,250	14,346	14,420	15,171	14,945	15,911	17,046	17,581	18,957	19,099	19,073	18,973	19,020	17,703	16,279	14,752	13,031	13,612	0	0	0
Research and development expenses
8,671	8,650	8,286	8,011	7,966	8,006	7,863	7,720	7,710	7,683	7,900	0	0	7,892	7,709	7,550	7,536	7,690	8,550	8,630	8,655	8,393	6,995	6,820	6,591	6,678	6,800	7,060	7,130	7,482	7,732	8,021	8,652	8,681	9,391	9,403	9,353	9,483	9,382	8,826	8,340	7,824	6,917	7,251	0	0	0
Amortization of intangible assets
4,312	4,610	4,832	4,873	4,880	4,893	4,827	4,751	4,768	4,758	4,692	0	0	4,056	3,914	3,883	3,794	3,728	3,698	3,733	3,862	4,039	4,213	4,358	4,497	4,599	4,679	4,773	4,908	5,109	5,222	5,400	5,509	5,465	5,541	5,308	5,331	5,364	5,094	4,532	3,708	2,877	2,376	2,445	0	0	0
Acquisition-related in-process research and development charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94	0	0	-	-	0	-	0	0
Restructuring charges and certain acquisition-related costs
770	747	1,168	888	1,047	1,044	255	284	310	351	845	0	0	1,565	1,413	1,463	1,233	1,152	857	257	252	250	755	1,007	1,109	1,182	1,264	1,343	1,344	1,810	1,472	2,250	2,544	2,841	3,517	2,926	3,333	3,145	5,214	4,908	4,482	4,330	1,572	1,948	0	0	0
(Gain) on completion of Consumer Healthcare JV transaction
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Nonoperating Income (Expense)
-3,707	-3,578	-3,796	-3,063	-2,386	-2,116	-209	-702	-1,178	-1,416	-1,043	0	0	-3,794	-5,005	-4,249	-3,236	-2,860	-1,015	-448	-340	-1,009	-646	-963	54	532	-225	-751	-2,509	-4,022	-3,972	-3,582	-3,317	-2,486	-2,702	-4,504	-4,356	-3,941	-3,496	-987	-640	-285	896	569	0	0	0
Income from continuing operations before provision for taxes on income
17,244	17,682	18,245	11,695	12,081	11,885	13,785	13,193	12,481	12,305	12,127	0	0	8,351	7,222	8,315	9,444	8,965	11,121	12,011	12,475	12,240	13,498	13,484	14,838	15,716	14,476	13,709	12,532	11,242	10,645	11,380	10,798	11,481	11,239	9,112	9,440	9,471	8,340	10,897	10,020	10,674	13,545	12,364	0	0	0
Provision for taxes on income
1,426	1,384	2,001	-980	583	706	-10,066	-9,405	-9,314	-9,049	2,301	0	0	1,123	921	1,239	1,797	1,990	2,723	3,067	3,244	3,120	3,005	3,079	3,779	4,306	4,389	3,221	2,619	2,221	2,142	3,541	3,438	3,621	1,175	517	912	1,153	2,358	2,892	2,206	2,145	3,415	2,348	0	0	0
Income from continuing operations
15,819	16,298	16,243	12,674	11,497	11,179	23,849	22,596	21,794	21,353	9,829	0	0	7,229	6,299	7,074	7,647	6,975	8,398	8,944	9,230	9,119	10,493	10,405	11,059	11,410	10,087	10,488	9,913	9,021	8,503	7,839	7,360	7,860	10,064	8,595	8,528	8,318	5,982	8,005	7,814	8,529	10,130	10,016	0	0	0
Discontinued operations:
Income from discontinued operations––net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	0	-	-	-19	0	0	0	-	-	-	-	-	-
Gain on disposal of discontinued operations––net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	0	-	-	-11	0	0	0	-	-	-	-	-	-
Discontinued operations––net of tax
4	4	4	11	11	10	10	-1	1	2	18	0	0	17	-2	6	6	11	-8	-19	-20	48	13	27	10,586	10,662	15,732	15,946	5,647	5,577	1,222	2,421	2,258	2,189	1,434	25	-41	-30	175	162	134	114	31	46	0	0	0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
15,823	16,302	16,246	12,684	11,507	11,188	23,860	22,596	21,795	21,355	9,846	0	0	7,246	6,297	7,081	7,653	6,986	8,392	8,925	9,211	9,168	10,505	10,432	21,645	22,072	25,819	26,434	15,560	14,598	9,725	10,260	9,618	10,049	11,498	8,620	8,487	8,288	6,157	8,167	7,948	8,643	10,161	10,062	0	0	0
Less: Net income attributable to noncontrolling interests
32	29	32	36	33	36	39	49	47	47	38	0	0	31	27	36	29	26	32	29	29	32	30	33	63	69	69	66	34	28	31	36	37	40	38	32	34	31	23	21	16	8	15	18	0	0	0
Net income attributable to Pfizer Inc.
15,790	16,273	16,216	12,650	11,476	11,153	23,821	22,547	21,748	21,308	9,809	0	0	7,215	6,268	7,043	7,622	6,960	8,360	8,896	9,182	9,135	10,475	10,399	21,582	22,003	25,750	26,368	15,526	14,570	9,694	10,224	9,581	10,009	11,460	8,588	8,453	8,257	6,134	8,146	7,932	8,635	10,146	10,044	0	0	0
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
0.61	-0.06	1.38	0.91	0.69	-0.06	0.70	0.66	0.60	2.05	0.48	0.52	0.52	0.13	0.22	0.34	0.49	-0.02	0.34	0.43	0.38	0.20	0.42	0.46	0.35	0.41	0.39	0.51	0.36	0.18	0.40	0.40	0.23	0.10	0.30	0.32	0.28	0.37	0.11	0.30	0.25	0.04	0.43	0.34	0.41	0.34	0.41
Discontinued operations––net of tax (in dollars per share)
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.04	0.00	1.50	0.02	0.68	0.03	0.03	0.01	0.09	0.18	0.01	0.00	-0.01	0.00	0.01	0.00	0.02	0.00	0.00	0.00	0.00	0.00
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)
0.61	-0.06	1.38	0.91	0.69	-0.06	0.70	0.66	0.60	2.05	0.48	0.52	0.52	0.13	0.22	0.34	0.49	-0.03	0.35	0.43	0.38	0.20	0.42	0.46	0.36	0.46	0.39	2.00	0.38	0.85	0.43	0.44	0.24	0.19	0.48	0.33	0.28	0.36	0.11	0.31	0.25	0.05	0.43	0.34	0.41	0.34	0.41
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
0.61	-0.06	1.36	0.89	0.68	-0.07	0.69	0.65	0.59	2.03	0.47	0.51	0.51	0.13	0.22	0.33	0.49	-0.03	0.34	0.42	0.38	0.19	0.42	0.45	0.35	0.40	0.39	0.50	0.36	0.17	0.40	0.40	0.23	0.09	0.30	0.32	0.28	0.37	0.11	0.30	0.25	0.04	0.43	0.34	0.40	0.33	0.41
Discontinued operations––net of tax (in dollars per share)
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.04	0.00	1.48	0.02	0.67	0.03	0.03	0.01	0.09	0.18	0.01	0.00	-0.01	0.00	0.01	0.00	0.02	0.00	0.00	0.00	0.01	0.00
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)
0.61	-0.06	1.36	0.89	0.68	-0.06	0.69	0.65	0.59	2.03	0.47	0.51	0.51	0.13	0.22	0.33	0.49	-0.03	0.34	0.42	0.38	0.19	0.42	0.45	0.36	0.44	0.39	1.98	0.38	0.84	0.43	0.43	0.24	0.18	0.48	0.33	0.28	0.35	0.11	0.31	0.25	0.06	0.43	0.34	0.40	0.34	0.41
Weighted-average shares––basic
5,545	5,534	5,545	5,562	5,635	5,790	5,875	5,866	5,957	5,965	5,951	5,958	6,006	6,072	6,066	6,068	6,150	6,174	6,168	6,159	6,203	6,297	6,330	6,368	6,389	6,442	6,581	7,042	7,187	7,319	7,436	7,476	7,537	7,641	7,770	7,875	7,982	8,010	8,027	8,046	8,061	7,847	6,730	6,728	6,723	6,718	6,732
Weighted-average shares––diluted
5,613	5,629	5,649	5,672	5,750	5,913	5,986	5,952	6,057	6,062	6,041	6,037	6,092	6,112	6,150	6,149	6,225	6,250	6,243	6,243	6,292	6,373	6,403	6,444	6,476	6,538	6,656	7,117	7,269	7,389	7,508	7,537	7,598	7,700	7,810	7,935	8,035	8,066	8,057	8,072	8,101	7,913	6,762	6,752	6,753	6,736	6,748
Cash dividends paid per common share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	0.32	0.32	0.32	-	0.30	0.30	0.30	0.28	0.28	0.28	0.28	0.26	0.26	0.26	0.26	0.24	0.24	0.24	0.24	0.22	0.22	0.22	0.22	0.20	0.20	0.20	0.20	0.18	0.18	0.18	0.18	-	0.16	0.16	0.32	0.32	0.32